Using heparin therapy to reverse protein-losing enteropathy in a patient with CDG-Ib
- PMID: 18285818
- DOI: 10.1038/ncpgasthep1061
Using heparin therapy to reverse protein-losing enteropathy in a patient with CDG-Ib
Abstract
Background: A 22-year-old female presented with edema, diarrhea, hypoalbuminemia and pancytopenia. She had previously been diagnosed with congenital disorder of glycosylation type Ib, and had a history of congenital hepatic fibrosis, portal hypertension and esophageal varices. In the past she had refused mannose therapy because of associated diarrhea and abdominal pain.
Investigations: Laboratory examinations, abdominal ultrasonography, bacterial and viral cultures of blood, urine and stools, double-balloon enteroscopy and fecal excretion test using 51Cr-labeled albumin.
Diagnosis: Protein-losing enteropathy.
Management: Infusion of albumin followed by intravenous and subcutaneous therapy with unfractionated heparin.
Similar articles
-
Reversal of protein-losing enteropathy with heparin therapy in an adult patient with congenital heart disease.Digestion. 2006;74(3-4):206-7. doi: 10.1159/000100505. Epub 2007 Mar 6. Digestion. 2006. PMID: 17341854 No abstract available.
-
Gastrointestinal and other clinical manifestations in 17 children with congenital disorders of glycosylation type Ia, Ib, and Ic.J Pediatr Gastroenterol Nutr. 2004 Mar;38(3):282-7. doi: 10.1097/00005176-200403000-00010. J Pediatr Gastroenterol Nutr. 2004. PMID: 15076627
-
The clinical spectrum of phosphomannose isomerase deficiency, with an evaluation of mannose treatment for CDG-Ib.Biochim Biophys Acta. 2009 Sep;1792(9):841-3. doi: 10.1016/j.bbadis.2008.11.012. Epub 2008 Dec 6. Biochim Biophys Acta. 2009. PMID: 19101627
-
Protein-losing enteropathy in systemic lupus erythematosus.Rev Hosp Clin Fac Med Sao Paulo. 1991 Jan-Feb;46(1):34-7. Rev Hosp Clin Fac Med Sao Paulo. 1991. PMID: 1843003 Review.
-
Genomic organization of the human phosphomannose isomerase (MPI) gene and mutation analysis in patients with congenital disorders of glycosylation type Ib (CDG-Ib).Hum Mutat. 2000 Sep;16(3):247-52. doi: 10.1002/1098-1004(200009)16:3<247::AID-HUMU7>3.0.CO;2-A. Hum Mutat. 2000. PMID: 10980531 Review.
Cited by
-
Inherited Thrombocytopenia Caused by Variants in Crucial Genes for Glycosylation.Int J Mol Sci. 2023 Mar 7;24(6):5109. doi: 10.3390/ijms24065109. Int J Mol Sci. 2023. PMID: 36982178 Free PMC article. Review.
-
Treatment Options in Congenital Disorders of Glycosylation.Front Genet. 2021 Sep 10;12:735348. doi: 10.3389/fgene.2021.735348. eCollection 2021. Front Genet. 2021. PMID: 34567084 Free PMC article. Review.
-
Liver Involvement in Congenital Disorders of Glycosylation and Deglycosylation.Front Pediatr. 2021 Jul 5;9:696918. doi: 10.3389/fped.2021.696918. eCollection 2021. Front Pediatr. 2021. PMID: 34291020 Free PMC article.
-
Etiology and Management of Pediatric Intestinal Failure: Focus on the Non-Digestive Causes.Nutrients. 2021 Feb 27;13(3):786. doi: 10.3390/nu13030786. Nutrients. 2021. PMID: 33673586 Free PMC article. Review.
-
MPI-CDG from a hepatic perspective: Report of two Egyptian cases and review of literature.JIMD Rep. 2020 Sep 7;56(1):20-26. doi: 10.1002/jmd2.12159. eCollection 2020 Nov. JIMD Rep. 2020. PMID: 33204592 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical
Miscellaneous